



## SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)

(Company Registration Number: 201134046D)

---

### INCREASE IN ISSUED AND PAID-UP SHARE CAPITAL OF PROTON THERAPY PTE. LTD.

---

The Board of Directors (the "**Board**") of Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce that Proton Therapy Pte. Ltd. ("**PTPL**"), a wholly-owned subsidiary of the Company, has issued 153,175,526 new ordinary shares at S\$1 per share to the Company on 27 March 2025, thereby increasing PTPL's issued and paid-up share capital from S\$2 divided into two ordinary shares to S\$153,175,528 divided into 153,175,528 ordinary shares (the "**Capital Increase**").

PTPL undertakes the Group's proton therapy business, which accounted for approximately 12% of the Group's revenue for the latest audited financial year ended 30 June 2024. Following the Capital Increase, PTPL continues to be a wholly-owned subsidiary of the Company.

The Capital Increase was satisfied by way of capitalisation of the Company's existing loan of S\$153,175,526.00 extended to PTPL to fund the general working capital of PTPL. PTPL is currently in the ramping-up phase, and the debt conversion provides the necessary financial stability required for sustainable growth. Over the long term, PTPL's enhanced financial position is expected to contribute positively to the Group's overall performance. With the issuance of new shares via debt conversion, the Company's investment cost increased from S\$2 to S\$153,175,528. These transactions are eliminated at the Group level, resulting in no financial impact on the Group's consolidated accounts.

The Capital Increase is not expected to have any material impact on the net tangible assets per share and earnings per share of the Group for the current financial year ending 30 June 2025.

None of the Directors or controlling shareholders of the Company and their respective associates has any interest, direct or indirect, in the Capital Increase, other than through their respective shareholdings (if any) in the Company.

#### BY ORDER OF THE BOARD

Dr Djeng Shih Kien  
Executive Director and Chief Executive Officer  
27 March 2025

---

Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg).